Company profile
Spero Therapeutics, Inc.
NASDAQ: SPRO · Healthcare · Biotechnology
#601 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
68BFH 91DQ 51GM 41SS 49
v0.1 · 65/100 weight · provisional
↑ operating margin, net margin · ↓ growth stability, 3-yr revenue growth
Methodology →Revenue TTM
$54.8M
Rev growth YoY (TTM)
+22.8%
Net income (FY)
$8.6M
Employees
25
as of 2026-08-14
Market cap
$71.8M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$12.6M$12.6M2025
Net income$8.6M$8.6M2025
Operating income$6.3M$6.3M2025
Total assets$68.9M$68.9M2025
Liabilities$9.9M$9.9M2025
Equity$59.0M$59.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenue Related Party70%
Collaboration Revenue19%
Grant Revenue11%
By geography
Not disclosed.
The read
What is Spero Therapeutics, Inc.’s revenue?
Spero Therapeutics, Inc. booked $12.6M in FY2025 revenue, growing 3292% year over year — faster than 98% of Healthcare companies we track, at a 68.1% net margin.
Peers · Healthcare
Tonix Pharmaceuticals Holding Corp.45DRadnostix, Inc.51DLeveljump Healthcare Corp.——Lumos Diagnostics Holdings Ltd.45DNexgenRx Inc.71BClearday, Inc.——Neighbors
Middlesex →Key facts
CEOEsther Rajavelu
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: SPRO
Employees25
IPO date2017-11-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.